Teva Pharmaceutical Industries (NYSE:TEVA) Raised to “Strong-Buy” at Wall Street Zen

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

A number of other research firms have also issued reports on TEVA. Jefferies Financial Group raised their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, December 22nd. The Goldman Sachs Group lifted their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $34.08 on Friday. The business’s 50-day simple moving average is $30.49 and its 200-day simple moving average is $23.15. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $34.11. The firm has a market cap of $39.09 billion, a price-to-earnings ratio of 28.40, a P/E/G ratio of 1.88 and a beta of 0.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 48.20% and a net margin of 8.16%.The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same period in the previous year, the company earned $0.71 EPS. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer owned 5,650 shares of the company’s stock, valued at $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mark Sabag sold 216,892 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the transaction, the insider directly owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 622,060 shares of company stock valued at $17,076,965 in the last 90 days. Insiders own 0.49% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently modified their holdings of TEVA. Grove Bank & Trust grew its position in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares during the period. Advisors Asset Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $41,000. Cromwell Holdings LLC boosted its stake in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares in the last quarter. MAI Capital Management grew its holdings in shares of Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the last quarter. Finally, Rothschild Investment LLC increased its position in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after purchasing an additional 1,348 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 fundamentals beat expectations — Teva reported stronger-than-expected results (reported EPS and revenue outperformed consensus), revenue grew year-over-year driven by a Sanofi milestone and Austedo growth, and management set FY‑2026 EPS guidance of roughly 2.57–2.77, supporting a higher valuation. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Barclays raised its price target to $38 and set an “overweight” rating, signaling upside from current levels and lending third‑party validation to the stock’s outlook. Barclays raises TEVA price target to $38
• Positive Sentiment: Truist increased its price target to $38 with a “buy” rating, reinforcing bullish analyst sentiment following the quarter. Truist raises TEVA price target to $38
• Positive Sentiment: Scotiabank lifted its target to $40 and moved to “sector outperform,” the highest target among recent broker notes, which may attract more investor interest. Scotiabank raises TEVA price target to $40

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.